Your shopping cart is currently empty

Zosuquidar (RS 33295-198) is a potent P-glycoprotein inhibitor with antitumor activity, inhibits tumor growth, significantly inhibits PD-L1 expression by triggering its autophagic degradation, and is used in the study of acute myeloid leukemia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $71 | - | In Stock | |
| 5 mg | $163 | - | In Stock | |
| 10 mg | $245 | - | In Stock | |
| 25 mg | $397 | - | In Stock | |
| 50 mg | $597 | - | In Stock | |
| 100 mg | $868 | - | In Stock | |
| 200 mg | $1,190 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $189 | - | In Stock |
| Description | Zosuquidar (RS 33295-198) is a potent P-glycoprotein inhibitor with antitumor activity, inhibits tumor growth, significantly inhibits PD-L1 expression by triggering its autophagic degradation, and is used in the study of acute myeloid leukemia. |
| In vitro | Zosuquidar (0.3 μM, treated for 48 hours) enhances the cytotoxic effect of DNR (P-glycoprotein substrate) in P-glycoprotein-active cell lines. [2] Zosuquidar (5-16 μM, treated for 72 hours) alone exhibited strong cytotoxicity in drug-sensitive cell lines and multidrug resistant (MDR) cell lines. [1] |
| In vivo | Intraperitoneal injection of 30, 10, 3, or 1 mg/kg Zosuquidar once daily for 5 days significantly prolonged subject survival. [1] Intraperitoneal injection of 30 mg/kg Zosuquidar once daily for 5 days observed a significant potentiation when combined with adriamycin (Doxorubicin). [1] |
| Synonyms | RS33295-198, RS 33295-198, LY-335979, LY335979 |
| Molecular Weight | 527.6 |
| Formula | C32H31F2N3O2 |
| Cas No. | 167354-41-8 |
| Smiles | FC1(F)[C@]2([C@@]1(C=3C([C@@H](C=4C2=CC=CC4)N5CCN(C[C@H](COC=6C7=C(C=CC6)N=CC=C7)O)CC5)=CC=CC3)[H])[H] |
| Relative Density. | 1.36 g/cm3 |
| Storage | store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (151.63 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.48 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.